Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
88 hedge funds and large institutions have $107M invested in Sorrento Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 16 closing their positions.
105% more capital invested
Capital invested by funds: $52.2M → $107M (+$55M)
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
4% more funds holding
Funds holding: 85 → 88 (+3)
34% less call options, than puts
Call options by funds: $2.27M | Put options by funds: $3.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$9.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.15M |
| 3 |
BlackRock
New York
|
+$1.29M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.2M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$712K |
| 2 |
Swiss National Bank
Zurich,
Switzerland
|
-$382K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$378K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$366K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$107K |
SRNE Hedge Fund Activity: Q4 2019 in Review
88 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2019, worth a combined $107M — up 105% from $52.2M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SRNE positions and 16 closed out — a net gain of 4 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $9.54M. The largest seller was Citadel Advisors, exiting entirely with an estimated $712K sold.
- 88 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2019, up from 85 in Q3 2019.
- Funds reported $107M of Sorrento Therapeutics, Inc. stock for Q4 2019, up 105% quarter-over-quarter.
- 20 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2019 and 16 closed out, a net change of +4 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2019 was Cormorant Asset Management, an estimated $9.54M added.
- The largest Sorrento Therapeutics, Inc. seller in Q4 2019 was Citadel Advisors, an estimated $712K sold.
Based on aggregated 13F filings for Q4 2019.